New Zealand markets open in 3 hours 55 minutes

GRI Bio, Inc. (GRI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.8696-1.1004 (-37.05%)
As of 01:59PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.9700
Open1.9400
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.7521 - 2.1000
52-week range1.7521 - 472.2900
Volume633,056
Avg. volume67,788
Market cap949,926
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-51.9500
Earnings date12 Aug 2024 - 16 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    GRI Bio Announces Reverse Stock Split

    GRI’s common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-13 reverse stock split (the “Reverse Split”) of the

  • GlobeNewswire

    Connect Biopharma Announces New Leadership and Chair of the Board of Directors

    Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-

  • GlobeNewswire

    GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference

    Live video webcast on Tuesday, June 18th at 11:00 AM ET LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 11:00 AM ET. As part of the event, Marc Hertz, PhD, Chief Execu